Clinical StudiesAcute versus chronic vertebral compression fractures treated with kyphoplasty: early results☆
Introduction
More than 1.5 million osteoporotic fractures occur in the United States each year, and the direct hospital and nursing home cost continues to increase from $17 billion in 2001 [1]. Approximately 700,000 of these osteoporotic fractures affect vertebrae [1]. Whereas both men and women are susceptible to the effects of osteoporosis, vertebral compression fractures (VCFs) have been estimated to affect 25% of women over age 50 years and 40% of women over age 80 years [2].
VCFs are associated with increased mortality and morbidity, including chronic pain, impaired physical function and decreased quality of life [3], [4], [5], [6]. For example, a 7% reduction in timed forced expiratory volume (FEV1) occurs with each thoracic-level fracture, and a decrease in pulmonary function is associated with both thoracic and lumbar fractures [7]. Patients who sustain one VCF are at a fivefold increased risk of sustaining additional fractures [8], [9], [10]. In a large prospective study, women over 65 years old with prevalent VCFs had a 23% increase in mortality compared with age-matched controls, and the mortality increased with the number of prevalent VCFs [11]. In addition, another study determined that 5 years after patients were diagnosed with VCFs, the observed survival rate was 61%, which was worse than the 76% expected survival rate [12].
Symptomatic VCFs may fail to respond to conservative treatment options, such as bed rest, analgesics and bracing. However, a minimally invasive technique for fracture reduction and stabilization (kyphoplasty) has recently been described as an alternative to medical therapy and open surgery [13], [14], [15]. Pain relief and vertebral height restoration in acute fractures have been reported with kyphoplasty [14], [16], [17]. We further analyze our data by fracture age in an attempt to refine the patient selection and treatment process, because the ideal treatment regimen has not been determined for patients with symptomatic vertebral compression fractures that do not respond to medical therapy. This is a prospective study to assess whether kyphoplasty patients with painful, acute fractures had better fracture correction and clinical outcome after surgery than kyphoplasty patients with painful chronic compression fractures.
Section snippets
Materials and methods
Eighty-six VCFs in 47 consecutive patients were treated with 55 kyphoplasty procedures from March 2000 to December 2001. The mean follow-up period was 18 months (range, 6 to 24 months). All patients had primary or secondary osteoporosis. All patients had a history of focal pain over the fracture site that persisted upon repeated clinical examination and that correlated with findings on imaging studies. Treatable fractures were diagnosed by a magnetic resonance imaging scan showing typical
Patients
The diagnosis for all but four patients was primary or secondary osteoporosis, as shown in Table 1. The mean follow-up time was 18 months (range, 6 to 24 months). The mean duration of symptoms for the acute and chronic fracture groups were 1.3 months and 11 months, respectively. The study included 35 (74.5%) women and 12 (25.5%) men, and the study group had a mean age of 74 years (range, 47 to 91years). The patient demographic information is summarized in Table 1.
Procedures and fractures
Of the 55 kyphoplasty
Discussion
To our knowledge, this is the first study to compare clinical and radiographic outcomes from acute versus chronic osteoporotic VCFs treated with kyphoplasty. In this series no balloon-related, cement-related or neurologic complications occurred with this minimally invasive procedure. The majority of patients in both of the acute and chronic fracture groups experienced excellent fracture-related pain relief after kyphoplasty. However, some continued to have residual pain. The mean preoperative
Conclusions
In the authors' opinion, kyphoplasty shows promise as a primary treatment option for all painful osteoporotic compression fractures. In our experience, VCFs treated before 10 weeks are more than five times as likely to be reducible (restoration to greater than 80% of estimated normal height) as fractures older than 4 months. Although our study suggests advantages to early referral for VCF reduction and stabilization with kyphoplasty, symptomatic chronic fractures should also remain candidates
References (31)
- et al.
Percutaneous balloon kyphoplasty for the correction of spinal deformity in painful vertebral body compression fractures
Clin Imaging
(2002) The clinical consequences of vertebral compression fracture
Bone
(1992)- et al.
Health professional's guide to rehabilitation of the patient with osteoporosis
Osteoporos Int
(2003) - et al.
Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989
J Bone Miner Res
(1992) - et al.
Quality of life issues in women with vertebral fractures due to osteoporosis
Arthritis Rheum
(1993) - et al.
Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group
Arch Intern Med
(2000) - et al.
Osteoporosis: etiology, diagnosis, and management
(1995) - et al.
Relationship of lung function to severity of osteoporosis in women
Am Rev Respir Dis
(1990) - et al.
Reduced pulmonary function in patients with spinal osteoporotic fractures
Osteoporos Int
(1998) - et al.
Pre-existing fractures and bone mass predict vertebral fracture incidence in women
Ann Intern Med
(1991)
Risk of new vertebral fracture in the year following a fracture
JAMA
Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis
J Bone Miner Res
Vertebral fractures and mortality in older women: a prospective study
Arch Intern Med
Population-based study of survival after osteoporotic fractures
Am J Epidemiol
New technologies in spine: kyphoplasty and vertebroplasty for the treatment of painful osteoporotic compression fractures
Spine
Cited by (133)
Early versus late percutaneous kyphoplasty for treating osteoporotic vertebral compression fracture: A retrospective study
2019, Clinical Neurology and NeurosurgeryCitation Excerpt :It could be the reason why early or late PKP yield similar VAS or ODI improvement. PKP has a potential advantage to partially reestablish vertebral height and thereby restore stability to the spine [22], and our results showed that postoperative height of the fractured vertebra restored significantly, and early PKP could lead to better restored vertebra height and restoration rate than late PKP. Our finding was consistent with the study of Crandall [22] and Erkan [23], and they believe that the timing of PKP affects restoration rate more in acute fractures than in chronic fractures.
Transforaminal Endoscopic Solution to a Kyphoplasty Complication: Technical Note
2016, World NeurosurgeryRadiologic study of disc behavior following compression fracture of the thoracolumbar hinge managed by kyphoplasty: A 52-case series
2016, Revue de Chirurgie Orthopedique et TraumatologiqueRadiologic study of disc behavior following compression fracture of the thoracolumbar hinge managed by kyphoplasty: A 52-case series
2016, Orthopaedics and Traumatology: Surgery and ResearchCitation Excerpt :The present study found a significant and lasting mean 5.7° correction of vertebral kyphosis at last follow-up, in agreement with the literature. Gain was 8° for Maestretti et al. [7], 7° for Crandall et al. [32] and 6° in the 2012 multicenter SFCR study [33]. In the present study, there was no significant change in VK after M3.
Position statement on percutaneous vertebral augmentation: A consensus statement developed by the society of interventional radiology (SIR), American association of neurological surgeons (AANS) and the congress of neurological surgeons (CNS), American college of radiology (ACR)
2014, Journal of Vascular and Interventional Radiology
- ☆
FDA device/drug status: approved, but not for this indication (PMMA).
Support in whole or in part was received from Kyphon, Inc. (Sunnyvale, CA). Author DC acknowledges a financial relationship (speaker and stockholder, Kyphon, Inc.), which may indirectly relate to the subject of this research.